Past and present of monitoring the functional immune response developed against Epstein-Barr and Adenovirus in hematopoietic stem cell transplantation
DOI:
https://doi.org/10.23938/ASSN.0121Keywords:
Hematopoietic stem cell transplantation. Viral infection. Immune reconstitution. Epstein–Barr virus. Adenovirus.Abstract
Epstein-Barr (EBV) and Adenovirus (AdV) viral infections represent a significant cause of morbi-mortality in allogeneic hematopoietic stem cell transplantation recipients due to the use of immunomyelosuppressive treatments and the prolonged period of immunodeficiency that they generate. To date, the post-transplant protective role of EBV and AdV specific CD8+ T lymphocytes (CTLs) has been demonstrated. However, other factors are increasingly important in regulating the reconstitution and activity of CTLs specific to these viruses such as different cell subpopulations (CD4 + T lymphocytes, regulatory T lymphocytes, dendritic cells, Natural Killer cells, etc.), molecular mechanisms of immunoregulation and the drugs administered to the patient as prophylaxis for a possible graft-versus-host disease. The aim of this review is to analyze the importance of monitoring the functional EBV and AdV-specific cellular response in the management of post-transplant recipients.
Downloads
References
GRATWOHL A, BRAND R, FRASSONI F, ROCHA V, NIEDERWIESER D, REUSSER P et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005; 36: 757-769.
LEEN AM, HESLOP HE, BRENNER MK. Antiviral T-cell therapy. Immunol Rev 2014; 258: 12-29.
HESLOP HE, SLOBOD KS, PULE MA, HALE GA, ROUSSEAU A, SMITH CA et al. Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood 2010; 115: 925-935.
FEUCHT J, OPHERK K, LANG P, KAYSER S, HARTL L, BETHGE W et al. Adoptive T-cell therapy with hexon-specific Th1 cells as a treatment of refractory adenovirus infection after HSCT. Blood 2015; 125: 1986-1894.
WANG J, QUAKE SR. RNA-guided endonuclease provides a therapeutic strategy to cure latent herpesviridae infection. Proc Natl Acad Sci U S A 2014; 111: 13157-13162.
THEMELI M, RIVIÈRE I, SADELAIN M. New cell sources for T cell engineering and adoptive immunotherapy. Cell Stem Cell 2015; 16: 357-366.
ALHO AC, KIM HT, CHAMMAS MJ, REYNOLDS CG, MATOS TR, FORCADE E et al. Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD. Blood 2016; 127: 646-657.
SEGGEWISS R, EINSELE H. Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 2010; 115: 3861-3868.
AULETTA JJ, LAZARUS HM. Immune restoration following hematopoietic stem cell transplantation: an evolving target. Bone Marrow Transplant 2005; 35: 835-857.
ITZYKSON R, ROBIN M, MOINS-TEISSERENC H, DELORD M, BUSSON M, XHAARD A et al. Cytomegalovirus shapes long-term immune reconstitution after allogeneic stem cell transplantation. Haematologica 2015; 100: 114-123.
RINGHOFFER S, ROJEWSKI M, DÖHNER H, BUNJES D, RINGHOFFER M. T-cell reconstitution after allogeneic stem cell transplantation: assessment by measurement of the sjTREC/βTREC ratio and thymic naive T cells. Haematologica 2013; 98: 1600-1608.
BORCHERS S, BREMM M, LEHRNBECHER T, DAMMANN E, PABST B, WÖLK B et al. Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogeneic stem cell transplantation. PLoS One 2012; 7: e50248. doi: 10.1371/journal.pone.0050248.
CHAUDHRY MS, VELARDI E, MALARD F, VAN DEN BRINK MR. Immune Reconstitution after Allogeneic Hematopoietic Stem Cell Transplantation: Time To T Up the Thymus. J Immunol 2017; 198: 40-46.
CLAVE E, BUSSON M, DOUAY C, PEFFAULT DE LATOUR R, BERROU J, RABIAN C et al. Acute graft-versus-host disease transiently impairs thymic output in young patients after allogeneic hematopoietic stem cell transplantation. Blood 2009; 113: 6477-6484.
MEHTA RS, REZVANI K. Immune reconstitution post allogeneic transplant and the impact of immune recovery on the risk of infection. Virulence 2016; 7: 901-916.
KIM SY, LEE DG, KIM MS, KIM HJ, LEE S, MIN CK. The influence of infection early after allogeneic stem cell transplantation on the risk of leukemic relapse and graft-versus-host disease. Am J Hematol 2008; 83: 784-788.
HU Y, CUI Q, YE Y, LUO Y, TAN Y, SHI J et al. Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Hematol Oncol 2017; 35: 118-124.
PASTORE D, DELIA M, MESTICE A, PERRONE T, CARLUCCIO P, GAUDIO F et al. Recovery of CMV-specific CD8+ T cells and Tregs after allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 550-557.
KENNEDY-NASSER AA, KU S, CASTILLO-CARO P, HAZRAT Y, WU MF, LIU H et al. Ultra low-dose IL-2 for GVHD prophylaxis after allogeneic hematopoietic stem cell transplantation mediates expansion of regulatory T cells without diminishing antiviral and antileukemic activity. Clin Cancer Res 2014; 20: 2215-2225.
WIKSTROM ME, FLEMING P, KUNS RD, SCHUSTER IS, VOIGT V, MILLER G et al. Acute GVHD results in a severe DC defect that prevents T-cell priming and leads to fulminant cytomegalovirus disease in mice. Blood 2015; 126: 1503-1514.
ULLAH MA, HILL GR, TEY SK. Functional Reconstitution of Natural Killer Cells in Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol 2016; 7: 144. doi: 10.3389/fimmu.2016.00144.
NGUYEN S, KUENTZ M, VERNANT JP, DHEDIN N, BORIES D, DEBRÉ P et al. Involvement of mature donor T cells in the NK cell reconstitution after haploidentical hematopoietic stem-cell transplantation. Leukemia 2008; 22: 344-352.
HUENECKE S, CAPPEL C, ESSER R, PFIRRMANN V, SALZMANN-MANRIQUE E, BETZ S et al. Development of Three Different NK Cell Subpopulations during Immune Reconstitution after Pediatric Allogeneic Hematopoietic Stem Cell Transplantation: Prognostic Markers in GvHD and Viral Infections. Front Immunol 2017; 8: 109. doi: 10.3389/fimmu.2017.00109.
SHILLING HG, MCQUEEN KL, CHENG NW, SHIZURU JA, NEGRIN RS, PARHAM P. Reconstitution of NK cell receptor repertoire following HLA-matched hematopoietic cell transplantation. Blood 2003; 101: 3730-3740.
CHEN C, BUSSON M, ROCHA V, APPERT ML, LEPAGE V, DULPHY N et al. Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant 2006; 38: 437-444.
SCHMID ET, PANG IK, CARRERA SILVA EA, BOSURGI L, MINER JJ, DIAMOND MS et al. AXL receptor tyrosine kinase is required for T cell priming and antiviral immunity. Elife 2016; 5. doi: 10.7554/eLife.12414.
HESLOP HE. How I treat EBV lymphoproliferation. Blood 2009; 114: 4002-4008.
UHLIN M, WIKELL H, SUNDIN M, BLENNOW O, MAEURER M, RINGDEN O et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica 2014; 99: 346-352.
ROUCE RH, LOUIS CU, HESLOP HE. Epstein-Barr virus lymphoproliferative disease after hematopoietic stem cell transplant. Curr Opin Hematol 2014; 21: 476-481.
WAGNER HJ, CHENG YC, HULS MH, GEE AP, KUEHNLE I, KRANCE RA et al. Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 2004; 103: 3979-3981.
STYCZYNSKI J, VAN DER VELDEN W, FOX CP, ENGELHARD D, DE LA CAMARA R, CORDONNIER C et al. Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica 2016; 101: 803-811.
XU LP, ZHANG CL, MO XD, ZHANG XH, CHEN H, HAN W et al. Epstein-Barr virus-related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. Biol Blood Marrow Transplant 2015; 21: 2185-2191.
BIAN Z, LIU J, XU LP, CHANG YJ, WANG Y, ZHANG XH et al. Association of Epstein-Barr virus reactivation with the recovery of CD4/CD8 double-negative T lymphocytes after haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplant 2017; 52: 264-269.
ICHEVA V, KAYSER S, WOLFF D, TUVE S, KYZIRAKOS C, BETHGE W et al. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J Clin Oncol 2013; 31: 39-48.
D'AVENI M, AÏSSI-ROTHÉ L, VENARD V, SALMON A, FALENGA A, DECOT V et al. The clinical value of concomitant Epstein Barr virus (EBV)-DNA load and specific immune reconstitution monitoring after allogeneic hematopoietic stem cell transplantation. Transpl Immunol 2011; 24: 224-232.
ANNELS NE, KALPOE JS, BREDIUS RG, CLAAS EC, KROES AC, HISLOP AD et al. Management of Epstein-Barr virus (EBV) reactivation after allogeneic stem cell transplantation by simultaneous analysis of EBV DNA load and EBV-specific T cell reconstitution. Clin Infect Dis 2006; 42: 1743-1748.
MEIJ P, VAN ESSER JW, NIESTERS HG, VAN BAARLE D, MIEDEMA F, BLAKE N et al. Impaired recovery of Epstein-Barr virus (EBV)--specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease. Blood 2003; 101: 4290-4297.
CALAROTA SA, CHIESA A, ZELINI P, COMOLLI G, MINOLI L, BALDANTI F. Detection of Epstein-Barr virus-specific memory CD4+ T cells using a peptide-based cultured enzyme-linked immunospot assay. Immunology 2013; 139: 533-544.
ISON MG. Adenovirus infections in transplant recipients. Clin Infect Dis 2006; 43: 331-339.
MATTHES-MARTIN S, FEUCHTINGER T, SHAW PJ, ENGELHARD D, HIRSCH HH, CORDONNIER C et al. European guidelines for diagnosis and treatment of adenovirus infection in leukemia and stem cell transplantation: summary of ECIL-4 (2011). Transpl Infect Dis 2012; 14: 555-563.
ROBIN M, MARQUE-JUILLET S, SCIEUX C, PEFFAULT DE LATOUR R, FERRY C, ROCHA V et al. Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcome. Haematologica 2007; 92: 1254-1257.
LINDEMANS CA, LEEN AM, BOELENS JJ. How I treat adenovirus in hematopoietic stem cell transplant recipients. Blood 2010; 116: 5476-5485.
CHAKRABARTI S, MAUTNER V, OSMAN H, COLLINGHAM KE, FEGAN CD, KLAPPER PE et al. Adenovirus infections following allogeneic stem cell transplantation: incidence and outcome in relation to graft manipulation, immunosuppression, and immune recovery. Blood 2002; 100: 1619-1627.
HIWARKAR P, GASPAR HB, GILMOUR K, JAGANI M, CHIESA R, BENNETT-REES N et al. Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. Bone Marrow Transplant 2013; 48: 803-808.
MUÑOZ-COBO B, SOLANO C, COSTA E, BRAVO D, CLARI M, BENET I et al. Dynamics of cytomegalovirus (CMV) plasma DNAemia in initial and recurrent episodes of active CMV infection in the allogeneic stem cell transplantation setting: implications for designing preemptive antiviral therapy strategies. Biol Blood Marrow Transplant 2011; 17: 1602-1611.
BORDIGONI P, CARRET AS, VENARD V, WITZ F, LE FAOU A. Treatment of adenovirus infections in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2001; 32: 1290-1297.
ZANDVLIET ML, FALKENBURG JH, VAN LIEMPT E, VELTROP-DUITS LA, LANKESTER AC, KALPOE JS et al. Combined CD8+ and CD4+ adenovirus hexon-specific T cells associated with viral clearance after stem cell transplantation as treatment for adenovirus infection. Haematologica 2010; 95: 1943-1951.
FEUCHTINGER T, LÜCKE J, HAMPRECHT K, RICHARD C, HANDGRETINGER R, SCHUMM M et al. Detection of adenovirus-specific T cells in children with adenovirus infection after allogeneic stem cell transplantation. Br J Haematol 2005; 128: 503-509.
GUÉRIN-EL KHOUROUJ V, DALLE JH, PÉDRON B, YAKOUBEN K, BENSOUSSAN D, CORDEIRO DJ et al. Quantitative and qualitative CD4 T cell immune responses related to adenovirus DNAemia in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2011; 17: 476-485.
TISCHER S, GEYEREGGER R, KWOCZEK J, HEIM A, FIGUEIREDO C, BLASCZYK R et al. Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection. J Transl Med 2016; 14:286. doi: 10.1186/s12967-016-1042-2.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Anales del Sistema Sanitario de Navarra
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
La revista Anales del Sistema Sanitario de Navarra es publicada por el Departamento de Salud del Gobierno de Navarra (España), quien conserva los derechos patrimoniales (copyright ) sobre el artículo publicado y favorece y permite la difusión del mismo bajo licencia Creative Commons Reconocimiento-CompartirIgual 4.0 Internacional (CC BY-SA 4.0). Esta licencia permite copiar, usar, difundir, transmitir y exponer públicamente el artículo, siempre que siempre que se cite la autoría y la publicación inicial en Anales del Sistema Sanitario de Navarra, y se distinga la existencia de esta licencia de uso.
